Alnylam Pharmaceuticals and Ribopharma merge to create leader in RNA interference

Published: 8-Jul-2003

Alnylam Pharmaceuticals, of Cambridge, Massachusetts, and German company Ribopharma have merged to create a leading international player in the field of therapeutic RNA interference (RNAi).


Alnylam Pharmaceuticals, of Cambridge, Massachusetts, and German company Ribopharma have merged to create a leading international player in the field of therapeutic RNA interference (RNAi).

The company will have its global hq in Cambridge, Massachusetts, and will have operating units there and in and Kulmbach, Germany, each with specific responsi-bilities including RNAi research and development. Dr John Maraganore, formerly president and ceo of Alnylam, will head up the merged company.

Concurrent with the merger, the combined entity has secured an additional US$24.6m (€21.5m) in private equity financing. The funding will be used to accelerate the company's research and commercial initiatives in RNAi-based therapeutics, while expanding its commercial and scientific teams.

The merger will result in increased competitive strengths and synergies. The company will have a formidable worldwide intellectual property estate, which includes patents in the fundamental technology of RNAi from Alnylam and core patents relating to product composition and therapeutic applications of RNAi from Ribopharma. In addition, the company will have the foundation of a strong product-generating engine for RNAi therapeutics, based on the pioneering research and development programmes of Alnylam and Ribopharma.

'We are positioned to be the leader in RNAi, one of the most exciting new areas of drug innovation seen in decades,' said Dr Maraganore. 'Our combined team, intellectual property portfolio, financial resources, and drug discovery and development capabilities position us to deliver on the promise of RNAi-based therapeutics to meet unmet medical needs for many important diseases.'

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Manufacturing

Limula partners with leading cancer centre to improve blood product processing for stem cell transplantation

The company will collaborate with Institut Paoli-Calmettes to advance haematopoietic stem cell (HSC) processing for transplants
Subscribe now